Browse regulations

Amendment to regulations governing the collection of levies and charges from primary industries (agriculture, farming, etc.). The instrument prescribes mechanisms for mandatory collection, reporting, and enforcement of industry levies likely used to fund government-administered programs such as research, marketing, and biosecurity.

This regulatory instrument imposes compulsory financial burdens and administrative compliance costs on primary producers—the very sector that underpins Australia's rural prosperity. Levy collection creates misaligned incentives, distorts resource allocation, and entrenches bureaucratic control over industry funding. The same objectives (research, biosecurity, marketing) could be achieved more efficiently through voluntary industry associations, user-pays services, or targeted general revenue funding, without the deadweight loss of forced extraction and compliance overhead. Such mandatory levies violate the principle of property rights and often lead to mission creep, funding projects producers neither want nor need.

Amendment to Primary Industries (Customs) Charges Regulations, modifying customs charges (import levies) on primary industry products such as beef, wool, wheat, dairy, and other agricultural commodities. Authorized by the Primary Industries (Excise) Levies Act 1999, these regulations impose border taxes on imports to fund industry organizations and activities.

Customs charges on primary industry imports function as protectionist tariffs that raise costs for businesses and consumers, distort trade patterns, and benefit domestic producers at public expense. While the specific 2004 amendment text is unavailable, the regulatory framework itself imposes costs through higher import prices, compliance burdens on importers, and competitive distortions in the market. Such charges represent government-enforced wealth transfer from consumers and importers to industry bodies, contradicting principles of liberty and free markets. The resources sector and agricultural exporters—Australia's prosperity backbone—face compounded regulatory burden through these border charges layered onto other compliance costs.

Repeals specific quarantine requirements for the Cocos (Keeling) Islands, removing regulatory barriers to trade and travel.

Deleting would reinstate burdensome quarantine rules, imposing compliance costs and hindering economic activity without clear biosecurity benefit, reducing prosperity and liberty.

A repeal regulation that abolishes the Extradition ( Republic of Croatia ) Regulations, terminating specific bilateral extradition arrangements with Croatia.

Deleting would restore obsolete extradition provisions, burdening law enforcement with unnecessary compliance and creating legal uncertainty around international criminal cooperation. The repeal instrument achieves this clean-up definitively and would be difficult to replicate through other means.

Repeals the Australian Tourist Commission and associated regulations, effectively deregulating Australian tourism promotion activities. Instrument was registered in 2009, removing the statutory framework of the former government tourism body.

This instrument is already operative — it repealed the Australian Tourist Commission in 2009 and its continued presence on the statute books serves no ongoing function. The repeal itself removed regulatory burden from the tourism sector, yet retaining this historical artifact provides no benefit. Keeping it creates unnecessary legislative clutter with no corresponding liberty or prosperity gain, while deletion would have no practical effect on Australians.

Repeals the Australian Tourist Commission (Allowances) Regulations, ending the legal basis for commission-administered allowances.

It efficiently eliminates distortionary subsidies and reduces regulatory burden; deleting it would require new legislation to reinstate the prior regime, increasing costs and market interference.

Amends the Health Insurance (Pathology Services Table) Regulations to update the Medicare Benefits Schedule (MBS) for pathology services, specifying fees and rebates for various diagnostic tests.

The regulation adds unnecessary complexity and compliance costs to the healthcare system. It creates barriers to entry for new providers and limits competition, which could drive down prices and improve service quality. Additionally, the fees and rebates specified may not reflect current market conditions or technological advancements, leading to inefficiencies and potential overutilization of certain tests.

Amends the General Medical Services Table to specify services covered by health insurance, likely aiming to standardize coverage for medical procedures.

The regulation imposes unnecessary bureaucratic constraints on healthcare providers and patients, inflates insurance premiums through rigid coverage definitions, and fails to address the dynamic needs of medical practice. Its 2004 origin suggests obsolescence, with potential unintended consequences like reduced access to essential services and stifled innovation in healthcare delivery.

Amends the Health Insurance (Diagnostic Imaging Services Table) to update the list of eligible diagnostic imaging services and their corresponding fees

The regulation created a rigid and centrally planned pricing mechanism, which can lead to inefficiencies and restrict innovation in the diagnostic imaging services market, ultimately increasing costs for consumers and reducing access to better options

Amends the Health Insurance (Pathology Services Table) to update Medicare coverage and reimbursement rates for pathology services.

Keeping this instrument perpetuates government control over healthcare markets, distorting incentives, imposing compliance costs, and stifling innovation in diagnostic services. The centralized table prevents price competition and patient choice, leading to inefficiency and higher costs. Repealing it would allow a free market to deliver better outcomes.

This instrument amends the General Medical Services Table (GMST), which defines the Medicare Benefits Schedule (MBS) - the schedule of medical services and associated Medicare rebates payable to practitioners. It modifies item descriptors, adds new medical service items, or adjusts benefit rates for specific procedures and consultations under Australia's universal health insurance scheme.

This regulation embodies price controls in healthcare that distort market signals, create artificial shortages in underfunded service areas, generate perverse billing incentives (upcoding, supplier-induced demand), and impose significant compliance burden on practitioners navigating thousands of complex MBS items. While practical transition challenges exist if deleted, the underlying framework should be fundamentally reformed rather than maintained - Australians would benefit from a system that allows genuine price competition in healthcare rather than centralized price-setting that consistently overpays for some services while undercompensating others, ultimately harming both patients and practitioners through misallocated resources and restricted choice.

Amends the Diagnostic Imaging Services Table under the Health Insurance Act to determine which imaging services receive Medicare benefits and set their rebate amounts, effectively controlling prices and mandating coverage for specific procedures.

Price controls distort market signals, leading to under-provision of services, reduced quality, and slower adoption of new technologies. Mandated coverage limits consumer choice and stifles private insurance innovation. The unseen costs include longer wait times, misallocation of resources, and the crowding out of competitive market solutions that would otherwise expand access and improve efficiency.

Amendment to the Medicare Benefits Schedule (MBS) that modifies coverage rules, item descriptors, and benefit amounts for general medical services. This regulation is part of the ongoing adjustment of what procedures Medicare subsidizes and at what rates, affecting reimbursement levels for doctors and access patterns for patients.

This regulation perpetuates Medicare's price-control mechanism on medical services, which distorts healthcare markets by setting maximum prices below equilibrium, reducing provider supply and creating artificial shortages. The MBS system itself creates moral hazard through third-party payment, inflates healthcare costs, and removes price signals that would otherwise guide efficient resource allocation. Government determination of 'appropriate' medical service values is inherently paternalistic and substitutes bureaucratic judgment for individual choice. Rather than addressing healthcare access through subsidy, a freer market approach would allow competition, price transparency, and voluntary insurance to serve consumers more efficiently.

Amendment to the General Medical Services Table regulating Medicare Benefits Schedule item descriptors, fees, and conditions for medical services. Establishes the regulated prices and conditions for government-subsidized medical procedures, affecting what doctors can charge and patients can claim for consultations, procedures, and treatments under Australia's Medicare system.

This instrument maintains price controls on medical services through the Medicare Benefits Schedule, distorting healthcare markets by fixing fees rather than allowing competitive pricing. Such regulation restricts supply, creates bulk-billing distortions, discourages innovation in service delivery, and layers compliance costs on medical practitioners. Australians would be better served by a system where medical pricing emerges from voluntary contracts and genuine competition, not bureaucratic fee-setting.

Amended the Health Insurance (General Medical Services Table) Regulations to modify Medicare Benefits Schedule (MBS) item descriptors, fees, and eligibility criteria for various medical services. These regulations prescribe which medical services are eligible for Medicare rebates and the maximum benefit amounts payable, affecting what doctors and patients can claim for consultations, procedures, and specialist services across Australia's public health insurance system.

Government price-fixing of medical fees through the MBS creates artificial supply-demand imbalances, distorting healthcare markets. The regulation assumes bureaucrats can set appropriate fees across all medical specialties and regions — an economic calculation problem Mises identified. Unintended consequences include bulk-billing deserts in rural areas, specialist shortages, prolonged wait times, and barriers to innovation in medical technology. Friedman argued healthcare markets could function with consumer sovereignty and targeted safety nets rather than comprehensive price controls. A system of targeted vouchers or tax incentives for low-income Australians would achieve access goals without centralized fee-setting that harms all Australians through reduced supply and longer wait times.